COSCIENS BIOPHARMA INC (CSCI.CA) Stock News

Canada - TSX:CSCI - CA22112H1010 - Common Stock

3.5 CAD

+0.04 (+1.16%)

Last: 11/11/2025, 7:00:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CSCI.CA Latest News, Press Relases and Analysis

All

Press Releases

17 hours ago - By: COSCIENS Biopharma Inc. - Mentions: CSCI

COSCIENS Biopharma Inc. Reports Third Quarter 2025 Financial Results and Provides Strategic Initiatives Update

3 months ago - By: COSCIENS Biopharma Inc. - Mentions: CSCI

COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update

4 months ago - By: COSCIENS Biopharma Inc. - Mentions: CSCI

COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders

6 months ago - By: COSCIENS Biopharma Inc. - Mentions: CSCI

COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders

6 months ago - By: COSCIENS Biopharma Inc. - Mentions: CSCI

COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders

6 months ago - By: COSCIENS Biopharma Inc. - Mentions: CSCI

COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update

7 months ago - By: COSCIENS Biopharma Inc. - Mentions: CSCI

COSCIENS Biopharma Inc. Appoints Global Consumer Products and Biosciences Executive, Anna Biehn as Chief Executive Officer

7 months ago - By: COSCIENS Biopharma Inc. - Mentions: CSCI

COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

7 months ago - By: COSCIENS Biopharma Inc. - Mentions: CSCI

COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order

8 months ago - By: COSCIENS Biopharma Inc. - Mentions: CSCI

COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents

8 months ago - By: COSCIENS Biopharma Inc. - Mentions: CSCI

COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product

a year ago - By: COSCIENS Biopharma Inc. - Mentions: CSCI

COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization

a year ago - By: COSCIENS Biopharma Inc. - Mentions: CSCI

COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs

a year ago - By: COSCIENS Biopharma Inc. - Mentions: CSCI

COSCIENS Biopharma Announces Change to Board of Directors

a year ago - By: COSCIENS Biopharma Inc. - Mentions: CSCI

COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director

a year ago - By: COSCIENS Biopharma Inc. - Mentions: CSCI

COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs

a year ago - By: COSCIENS Biopharma Inc. - Mentions: CSCI

COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

a year ago - By: COSCIENS Biopharma Inc. - Mentions: CSCI

COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results